Download Library

Download Library
Document Type
Final results of a first-in-human study evaluating the safety, pharmacology and initial efficacy of MM-151, an oligoclonal anti-EGFR antibody in patients with refractory solid tumors
A Phase 1b/2 study combining MM-151 + nal-IRI + 5-FU + leucovorin in RAS-wild type metastatic colorectal cancer (mCRC)
Randomized Phase 2 study of paclitaxel (PTX), trastuzumab (T) with or without MM-111 in HER2 expressing gastroesophageal cancers (GEC)
SHERLOC: A Phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC)
HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1)
A Phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers
Identification of Heregulin (HRG) expression as a driver of a difficult-to-treat cancer phenotype and development of a companion diagnostic for the HRG-ErbB3 targeting drug seribantumab
A Randomized Trial of Exemestane +/- Seribantumab (MM-121) in Postmenopausal Women With Locally Advanced or Metastatic ER/PR+ HER2- Breast Cancer: Final Analysis and Extended Subgroup Analysis
Nanoliposomal targeting of Ephrin receptor A2 (EphA2): Clinical translation
Activity of an EphA2-targeted docetaxel nanoliposome in pancreatic patient-derived models as monotherapy and in combination with gemcitabine
= add file to Briefcase

In this section, you will find several of Merrimack’s high-resolution images. All images here are copyrighted by Merrimack Pharmaceuticals, Inc., and are made available here for editorial use only. By downloading and/or using any of the Merrimack’s images, you acknowledge the rights of Merrimack’s images, and you agree to comply with the usage guidelines.


Accept | Decline